Cardiac


  • A nighttime shot of Chicago's downtown and river.
    Image attribution tooltip
    halbergman via Getty Images
    Image attribution tooltip

    Top medtech conferences in 2025

    The lineup includes industry wide conferences and events covering the latest medtech trends in diabetes, orthopedics, cardiac care and surgical robotics.

    By Oct. 1, 2024
  • An anatomical heart is pictured in red in a transparent body.
    Image attribution tooltip
    magicmine via Getty Images
    Image attribution tooltip

    Recalled heart devices had limited clinical testing, study finds

    Just 30 of 157 heart devices with Class I recalls underwent premarket clinical testing, according to a study published in the Annals of Internal Medicine.

    By Sept. 24, 2024
  • Exterior view of a building with columns and a sign that says "Cook."
    Image attribution tooltip
    Courtesy of Cook Medical
    Image attribution tooltip

    Merit Medical inks $210M takeover of Cook’s lead management business

    Merit predicts the portfolio, which includes devices used in procedures to remove or replace heart rhythm device leads, will add $40 million a year to its sales.

    By Sept. 18, 2024
  • An image of Spectrawave's Hypervue intravascular imaging system.
    Image attribution tooltip
    Courtesy of Spectrawave
    Image attribution tooltip

    J&J leads $50M financing for imaging company Spectrawave

    The Series B round will support commercial expansion and product additions for Spectrawave’s system used in the treatment of coronary artery disease.

    By Sept. 11, 2024
  • A person in a blue shirt applies a blood pressure cuff to a person wearing a cardigan.
    Image attribution tooltip
    SDI Productions via Getty Images
    Image attribution tooltip

    European heart group recommends renal denervation for some patients

    The European Society of Cardiology said the treatment may be considered for certain patients with uncontrolled, drug-resistant high blood pressure but outlined lingering concerns.

    By Sept. 4, 2024
  • V-Wave's implantable device for heart failure is shown next to a dime.
    Image attribution tooltip
    Permission granted by Johnson & Johnson
    Image attribution tooltip

    J&J to buy heart failure implant maker V-Wave for up to $1.7B

    J&J has agreed to pay $600 million upfront for the private company as it works to expand its portfolio of cardiovascular devices.

    By Aug. 20, 2024
  • An inage of Edwards Lifesciences' Irvine, California, campus at dusk.
    Image attribution tooltip
    Courtesy of Edwards Lifesciences
    Image attribution tooltip

    Edwards spends $1.2B on 2 heart device firms, extending deal streak

    Alongside the acquisitions, Edwards reported a slowdown in its core TAVR business in the second quarter that sent its shares tumbling.

    By July 25, 2024
  • Photo of Michael F. Mahoney, CEO of Boston Scientific.
    Image attribution tooltip
    Courtesy of Boston Scientific
    Image attribution tooltip

    Boston Scientific tips strong growth for Farapulse after successful launch

    Questions on Boston Scientific’s pulsed field ablation system once again dominated the company’s earnings call.

    By July 24, 2024
  • Medtronic's Stacey Churchwell is pictured wearing a blue suit jacket and white shirt.
    Image attribution tooltip
    Permission granted by Medtronic
    Image attribution tooltip
    Q&A

    ‘Our next frontier is prediction’: Medtronic on AI and heart disease

    Stacey Churchwell, who leads the company’s cardiovascular diagnostics and services business, says artificial intelligence is reducing false positives in its insertable cardiac monitors, saving clinicians valuable time.

    By July 22, 2024
  • An image of the Abbott Volt pulsed field ablation catheter.
    Image attribution tooltip
    Permission granted by Abbott
    Image attribution tooltip

    Abbott previews PFA, over-the-counter CGM markets

    Electrophysiology sales held up against rivals’ launches of pulsed field ablation systems. Meanwhile, Abbott is gauging sales of its first OTC CGMs. 

    By July 18, 2024
  • A corporate building for Edwards Lifesciences.
    Image attribution tooltip
    Courtesy of Edwards Lifesciences
    Image attribution tooltip

    Edwards to acquire Innovalve, stake in Affluent Medical

    The heart valve specialist said in a federal filing that it expects to pay $300 million in cash for Innovalve Bio Medical when the deal closes.

    By July 15, 2024
  • A picture of a doctor looking at an X-ray screen during a procedure.
    Image attribution tooltip
    Permission granted by Boston Scientific
    Image attribution tooltip

    PFA devices are changing AFib treatment. The next wave could grow the market further.

    New pulsed field ablation systems from Boston Scientific and Medtronic are already reshaping the cardiac ablation market, but upcoming devices could spur even greater adoption.

    By June 17, 2024
  • Image attribution tooltip
    Fotolia
    Image attribution tooltip

    Kardium raises $104M to develop pulsed field ablation system

    Kardium will use the funding to complete a clinical study for pursuing regulatory approvals and build its manufacturing, clinical support and commercial teams.

    By June 12, 2024
  • Food And Drug Administration Headquarters In Maryland
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Abbott issues recall for Heartmate system monitor

    Abbott’s heart pump system and related products have been part of multiple Class I recalls this year.

    By June 11, 2024
  • Sapien valve performs equally well for small and large aortic annuli, Edwards finds

    The analysis adds to a debate about the effectiveness of Edwards versus Medtronic TAVR devices in patients with small aortic annuli, a fibrous ring around the heart’s valve.

    By June 6, 2024
  • An image of Medtronics PulseSelect pulsed field ablation system
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Medtronic touts demand for PFA, adding to hype for the new ablation tech

    CEO Geoff Martha told investors there has already been “strong adoption” of PFA devices and the category will be a big part of Medtronic's revenue growth in fiscal year 2025.

    By May 23, 2024
  • Photo of Michael F. Mahoney, CEO of Boston Scientific.
    Image attribution tooltip
    Courtesy of Boston Scientific
    Image attribution tooltip

    Boston Scientific’s cardiac rhythm system hits pivotal trial goals

    Boston Scientific, which presented the results at the Heart Rhythm Society meeting, expects to receive FDA approval for the system in 2025.

    By May 21, 2024
  • A photo of Johnson & Johnson's pulsed field ablation system for atrial fibrillation.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip

    J&J posts latest Varipulse data while awaiting FDA review

    Johnson & Johnson is chasing Medtronic and Boston Scientific in the U.S. for a share of the rapidly growing pulsed field ablation market.

    By May 20, 2024
  • A picture of Getinge's headquarters building in Gothenburg, Sweden.
    Image attribution tooltip
    Courtesy of Getinge
    Image attribution tooltip

    Getinge to limit US sales of heart devices after FDA safety warning

    CEO Mattias Perjos said the action will have “some negative financial impact,” but the total effect will depend on customers' response.

    By May 16, 2024
  • Abbott HeartMate 3 left ventricular assist device
    Image attribution tooltip
    Courtesy of Abbott
    Image attribution tooltip

    Abbott recalls Heartmate pump after 70 injuries, 2 deaths reported

    In the latest notice, which follows a February recall of the device for a separate issue, Abbott took action due to reports of blood leakage and air entrapment.

    By Updated May 16, 2024
  • The Getinge Cardiosave intra-aortic balloon pump system
    Image attribution tooltip
    Courtesy of Getinge
    Image attribution tooltip

    FDA tells providers to stop using Getinge heart devices

    After months of safety concerns, the FDA said Getinge has yet to “sufficiently” address the problems and risks.

    By May 9, 2024
  • The latest Apple Watch will include entirely fiber-based packaging for the first time
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    FDA qualifies Apple Watch AFib feature for use in clinical trials

    Officials will accept atrial fibrillation data collected by the wearable as a secondary endpoint in studies of cardiac ablation devices. 

    By May 6, 2024